Patents Issued in February 23, 2017
  • Publication number: 20170049786
    Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.
    Type: Application
    Filed: September 1, 2016
    Publication date: February 23, 2017
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Thierry NIVAGGIOLI, David A. WEBER, Philippe JM DOR, Philip REILLY
  • Publication number: 20170049787
    Abstract: The present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3?-ol and its derivatives, as well as a method for decreasing blood glucose and HbA1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood HDL-C levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (GLUT4) and phospho-Akt in skeletal muscle tissue, and phospho-AMPK in both skeletal muscle and liver tissue using ergostatrien-3?-ol and its derivatives.
    Type: Application
    Filed: January 29, 2016
    Publication date: February 23, 2017
    Inventor: Chun-Ching SHIH
  • Publication number: 20170049788
    Abstract: A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Inventors: Paul Nemeth, Matt Callahan, H. William Bosch, Marck Norret
  • Publication number: 20170049789
    Abstract: The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 23, 2017
    Inventors: Vinayak T. BHALANI, Anjan Kumar PAUL, Ashim Kumar Sarkar
  • Publication number: 20170049790
    Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a P13K inhibitor selected from PX-866, AZD6482, LY294002. BEZ235, GSK458, GDCO941, ZSTK474, BKM120 and GSK2636771B. Methods of treating cancer are also provided. The present invention is based in part on the inventor's discovery that combination therapy that targets mitochondria eliminates tumor adaptation induced by P13K inhibition, and improves clinical outcome in cancer.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Inventors: Dario C. Altieri, Jagadish C. Ghosh
  • Publication number: 20170049791
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Application
    Filed: November 9, 2016
    Publication date: February 23, 2017
    Inventor: Herriot Tabuteau
  • Publication number: 20170049792
    Abstract: The present invention provides a method of treating a subject afflicted with lupus nephritis comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.
    Type: Application
    Filed: May 4, 2015
    Publication date: February 23, 2017
    Inventor: Sheau-Long LEE
  • Publication number: 20170049793
    Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Applicants: THE GENERAL HOSPITAL CORPORATION, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
  • Publication number: 20170049794
    Abstract: A Pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and/or an anti-diabetic agent.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 23, 2017
    Inventors: Wen-Chin YANG, Lee-Tian CHANG
  • Publication number: 20170049795
    Abstract: Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.
    Type: Application
    Filed: July 29, 2016
    Publication date: February 23, 2017
    Inventor: David Lortscher
  • Publication number: 20170049796
    Abstract: A method of improving both motor function and cognitive function of healthy human subjects through administration of citicoline or its salt in high dosage or low dosage for a period of time, resulting in improved motor function and cognitive function.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 23, 2017
    Applicant: KYOWA HAKKO BIO CO., LTD.
    Inventors: Deborah Yurgelun-Todd, Perry Renshaw, Miho Takada, Takeshi Ikeda, Masahiko Morita
  • Publication number: 20170049797
    Abstract: The present invention relates to therapeutic combinations comprising faldaprevir, sofosbuvir, ledipasvir and, optionally, ribavirin, and methods of using such therapeutic combinations for treating HCV infection in a patient.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 23, 2017
    Inventor: Nezam H. AFDHAL
  • Publication number: 20170049798
    Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
    Type: Application
    Filed: April 24, 2016
    Publication date: February 23, 2017
    Inventors: Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
  • Publication number: 20170049799
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Inventors: William K. MCVICAR, Harun TAKRURI
  • Publication number: 20170049800
    Abstract: The invention is based on a finding that silencing CIP2A (KIAA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject.
    Type: Application
    Filed: September 1, 2016
    Publication date: February 23, 2017
    Applicant: Turun yliopisto
    Inventors: Jukka WESTERMARCK, Anna CVRLJEVIC
  • Publication number: 20170049801
    Abstract: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.
    Type: Application
    Filed: September 1, 2016
    Publication date: February 23, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Mary G. Prieve, Paul H. Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert W. Overell, Anna S. Gall, Amber E.E. Paschal, Charbel Diab, Priyadarsi De, Michael S. DeClue, Sean D. Monahan
  • Publication number: 20170049802
    Abstract: There is provided a method for treating rosacea comprising a composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 24, 2016
    Publication date: February 23, 2017
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Publication number: 20170049803
    Abstract: The invention provides compositions and methods of use thereof, in conjunction with the treatment and prevention of kidney and ureteral stones and related urinary tract conditions in man or in animals. Specifically provided are compositions formulated for direct instillation into the kidney, bladder, ureter, and urethra of the urinary tract before, during, and after the treatment of kidney and ureteral stones, such as with lithotripsy to alleviate or reduce at least one symptom associated therewith, and to facilitate the stones passing through the kidney, bladder, ureter, urethra and urinary tract. Compositions of the invention can comprise therapeutic amounts of: chondroitin sulfate and hyaluronan, and optionally include N-acetyl D-glucosamine.
    Type: Application
    Filed: May 4, 2015
    Publication date: February 23, 2017
    Inventor: Frank D. Marcum
  • Publication number: 20170049804
    Abstract: The instant invention provides a method and composition for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, said method comprising administering effective amounts of Boswellia Serrata, effective amounts of freeze dried green lipped mussle, effective amounts of white willow bark extract containing salicin, effective amounts of angelica root, effective amounts of glucosamine and salts thereof, effective amounts of chondroitin and salts thereof and effective amounts of omega 3 fatty acids.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Inventors: James Sullivan, Forrest Haag, Lianne Maso de Moya
  • Publication number: 20170049805
    Abstract: A water soluble polymer thin film of polyvinyl alcohol is manufactured and placed in contact with the skin, or through a buffering layer of cream, and then lightly sprayed on the exposed side with water to achieve conformal contact with the skin microstructures by transition from a solid state to a partial liquid/solid or gel state, and then upon drying back to a solid state. As the polymer thin film dries it contracts over a prolonged period, thereby producing a tightening effect of sustained tensile and compressive forces propagating through the skin surface layers with concurrent modulation of sensory nerve endings of the peripheral nervous system, with certain therapeutic effects depending upon the applied area, including reducing pain associated with arthritis or soreness of joint areas, inducing a relaxed and attentive cognitive state, inducing inflammation control or relief of cellular hydrostatic pressure, and reducing gastric reflex.
    Type: Application
    Filed: June 23, 2016
    Publication date: February 23, 2017
    Applicant: Transfer Devices, Inc.
    Inventor: Charles Schaper
  • Publication number: 20170049806
    Abstract: The present invention relates to a granular composition for oral suspension characterized by the presence of an insoluble resin and a silica gel.
    Type: Application
    Filed: August 19, 2015
    Publication date: February 23, 2017
    Inventors: Federico Stroppolo, Gabriele Granata
  • Publication number: 20170049807
    Abstract: Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 23, 2017
    Inventor: Gary S. HAHN
  • Publication number: 20170049808
    Abstract: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.
    Type: Application
    Filed: November 3, 2016
    Publication date: February 23, 2017
    Inventor: Hector F. DeLuca
  • Publication number: 20170049809
    Abstract: The present invention provides methods of stimulating angiogenesis and the growth or migration of cells associated with angiogenesis, by contacting animals, tissues, or cells with sulfide, alone or in combination with nitric oxide. These methods may be used for a variety or purposes, including promoting wound healings, increasing blood flow, and for the treatment and prevention of diseases and disorders associated with decreased blood flow, including ischemic or hypoxic injury.
    Type: Application
    Filed: March 28, 2016
    Publication date: February 23, 2017
    Inventor: Csaba Szabo
  • Publication number: 20170049810
    Abstract: The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with ?-amyloid deposition, preferably AD.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 23, 2017
    Applicant: AFFIRIS AG
    Inventors: Markus MANDLER, Achim SCHNEEBERGER, Wolfgang ZAUNER, Ame VON BONIN, Frank MATTNER, Walter SCHMIDT
  • Publication number: 20170049811
    Abstract: Disclosed are compositions and methods for providing a modified single dose all blood approach to cardioplegia and reanimation. The disclosed method of preserving a heart comprises of administering a cardiac arrest induction solution to the blood of a subject, perfusing the heart with the blood containing the cardiac arrest induction solution, and reanimating the heart with a cardiac reanimation solution. The cardiac arrest induction solution disclosed herein consists essentially of Potassium, a calcium channel blocker, a sodium channel blocker, and a free radical scavenger, while the cardiac reanimation solution comprises of calcium channel blocker and one or more of a sodium channel blocker, a beta receptor blocker, potassium, and a buffer.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Inventors: Catherine E. Berry, Candice Kalin
  • Publication number: 20170049812
    Abstract: The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 23, 2017
    Applicant: AFFIRIS AG
    Inventors: Markus MANDLER, Achim SCHNEEBERGER, Arne VON BONIN, Frank MATTNER, Walter SCHMIDT
  • Publication number: 20170049813
    Abstract: Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Applicant: OCULUS INNOVATIVE SCIENCES, INC.
    Inventor: Robert NORTHEY
  • Publication number: 20170049814
    Abstract: The present invention relates to a water suspension of graphene oxide nanoflakes decorated by nanoparticles of metallic platinum, characterised in that it comprises: ? 100 ?g/ml to 500 ?g/ml of graphene oxide nanoflakes, ? 5 ?g/ml to 50 ?g/ml of nanoparticles of metallic platinum (Pt°), deposited on the surface of graphene oxide nanoflakes. The invention also relates to a method of preparing such suspension and its use as an antitumor agent.
    Type: Application
    Filed: February 5, 2015
    Publication date: February 23, 2017
    Applicants: Szkola Glowna Gospodarstwa Wiejskiego, Instytut Technologii Materialow Elektronicznych
    Inventors: Ewa Sawosz Chwalibog, Marta Kutwin, Slawomir Jaworski, Mateusz Wierzbicki, Marta Grodzik, Anna Hotowy, Ludwika Lipinska, Joanna Jagiello
  • Publication number: 20170049815
    Abstract: This disclosure relates to methods of identifying subjects that have an increased likelihood of responding to a combination of a poly (ADP) ribose polymerase enzyme inhibitor and a platinum based reagent and optionally other anticancer agents in the course of chemotherapy. In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount of a poly (ADP) ribose polymerase enzyme inhibitor and a platinum based reagent to the subject in need thereof, wherein the subject is in need thereof because measuring a quantity of RNA isolated from a cancer cell from the subject indicates an increased quantity of the RNA compared to a normal sample, wherein the RNA is associated with one or more of the following genes/pseudogenes GLS, UBEC2, HACL1, MSI2, and LOC100129585.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Inventor: Taofeek Kunle Owonikoko
  • Publication number: 20170049816
    Abstract: Methods of benchmarking wellness are described herein.
    Type: Application
    Filed: March 31, 2014
    Publication date: February 23, 2017
    Inventor: Bristol Sorensen
  • Publication number: 20170049817
    Abstract: Methods and systems of processing exosomes from a biologic sample, including providing a biological sample having a mixed population of exosomes, wherein the mixed population of exosomes includes two or more distinct subpopulations of exosomes; processing the biological sample to selectively remove one or more exosome subpopulations from the mixed population of exosomes thereby obtaining a sample enriched with a desired subpopulation of exosomes; and adding the enriched sample of exosomes to a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 29, 2016
    Publication date: February 23, 2017
    Inventor: Allan Yang Wu
  • Publication number: 20170049818
    Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.
    Type: Application
    Filed: February 19, 2016
    Publication date: February 23, 2017
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Johannes L. Zakrzewski, Marcel R.m. Van Den Brink, Michel Sadelain
  • Publication number: 20170049819
    Abstract: The invention provides improved vector composition comprising chimeric antigen receptor for adoptive T cell therapies.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 23, 2017
    Inventors: Kevin Friedman, Byoung Ryu
  • Publication number: 20170049820
    Abstract: The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 23, 2017
    Inventors: Daniel Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
  • Publication number: 20170049821
    Abstract: Provided is a composition-of-matter comprising a microcapsule encapsulating mesenchymal stem cells, wherein at least 97% of cells in said microcapsule are said mesenchymal stem cells. Also provided are methods of generating and using the composition-of-matter.
    Type: Application
    Filed: September 4, 2016
    Publication date: February 23, 2017
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Marcelle MACHLUF, Amit GOREN
  • Publication number: 20170049822
    Abstract: An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 23, 2017
    Inventors: Qi LIU, Richard A.F. DIXON
  • Publication number: 20170049823
    Abstract: Provided is a pharmaceutical composition for preventing and treating ischemic disease, the composition including a cell cluster or a culture thereof; and an angiopoietin. The pharmaceutical composition is used to synergistically treat ischemic disease, compared to single administration of the effective ingredients, and the composition does not induce fibrosis in the administered area.
    Type: Application
    Filed: May 26, 2016
    Publication date: February 23, 2017
    Inventors: Sang Heon KIM, Kwi Deok PARK, Kang Won LEE, Jung Mi KANG
  • Publication number: 20170049824
    Abstract: The present invention provides methods for treating and preventing viral disease in farmed fish. In particular, the present invention relates to compositions and methods for improving heart health in farmed salmon.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 23, 2017
    Inventors: Sigve Nordrum, Harald Takle, Sven Martin Jørgensen, Trygve Sigholt
  • Publication number: 20170049825
    Abstract: Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type II arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects.
    Type: Application
    Filed: July 22, 2016
    Publication date: February 23, 2017
    Inventors: Ian Sims, Jonathan McDonald Counsell Stephens, Ralf Christian Schlothauer, Swapna Gannabathula
  • Publication number: 20170049826
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 23, 2017
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Publication number: 20170049827
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method may include a method of treating an infection. The method may comprise administering a microbiota restoration therapy composition to a patient with an infection. The microbiota restoration therapy composition may comprise a mixture of an effective amount of fecal microbiota and an effective amount of polyethylene glycol.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 23, 2017
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Publication number: 20170049828
    Abstract: The present invention provides a novel lactic acid bacterium having antioxidant and anti-aging functions and a dementia alleviation effect, and more specifically, provides Lactobacillus pentosus var. plantarum C29 KCCM11291P and Lactobacillus curvatus C3 KCCM430009. In addition, the present invention provides an antioxidant and anti-aging pharmaceutical composition and a dietary supplement containing the Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 of the present invention as an active ingredient, and a composition for preventing or treating dementia and a dietary supplement for preventing or alleviating dementia, containing Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 as an active ingredient. Additionally, the present invention provides a composition for preventing or treating dementia, containg a fermentation composition, as an active ingredient, fermented by Lactobacullus pentosus var.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 23, 2017
    Inventors: DONG-HYUN KIM, MYUNG JOO HAN, IL-HOON JUNG, MYUNG-AH JUNG
  • Publication number: 20170049829
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Application
    Filed: August 24, 2016
    Publication date: February 23, 2017
    Applicant: VIROCURE, INC.
    Inventors: Manbok KIM, Randal N. Johnston
  • Publication number: 20170049830
    Abstract: A purified lipid-based solution including cannabinoids is manufactured by providing a lipid solution including an array of triglycerides, cannabinoids and water soluble contaminants. Adding water to the lipid solution to create a mixture and heating the mixture in a pressure vessel to a temperature above the melting point of the lipid solution. The mixture is agitated to dissolve the water soluble contaminants and electrocoagulated. The mixture is cooled to cause the triglycerides and cannabinoids to solidify. The water is separated from the mixture to remove water soluble contaminants, precipitated contaminants, suspended solids and colloids from the mixture to yield a purified lipid solution.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 23, 2017
    Inventor: Joshua Michael Raderman
  • Publication number: 20170049831
    Abstract: A new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Also described is a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orally administering an effective dose of a thylakoid extract. Also described is an oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consist of water, physiological saline or propylene glycol. The thylakoid extract or composition is also provided as a food or a food supplement or as a pellet, or encapsulated granules or powder.
    Type: Application
    Filed: November 3, 2016
    Publication date: February 23, 2017
    Inventors: Marc Purcell, Rejean Drouin
  • Publication number: 20170049832
    Abstract: Disclosed is a composition containing a Dendropanax morbifera extract. The Dendropanax morbifera extract is used as an active ingredient for relieving stress, blocking UV light, and/or diffusing fragrance. The composition includes essential oil extracted from Dendropanax morbifera leaf, stem or sap, in which the Dendropanax morbifera extract is separated under optimal extraction conditions, which are determined by comparing and evaluating the components and yields of the essential oil, thus ensuring maximum efficacy and various applications of Dendropanax morbifera.
    Type: Application
    Filed: July 27, 2016
    Publication date: February 23, 2017
    Inventor: Seung Hun LEE
  • Publication number: 20170049833
    Abstract: The invention relates to Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: inflammatory bowel disease (IBD), all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, demyelinating neurological disorders including multiple sclerosis, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.
    Type: Application
    Filed: August 3, 2016
    Publication date: February 23, 2017
    Inventors: Emma Jane Blain, Victor Collin Duance, Ahmed Yasine Ali, Ifor Delme Bowen
  • Publication number: 20170049834
    Abstract: The present invention is directed to therapeutic methods for treating benign prostatic hyperplasia (BPH) in a subject comprising administering an effective amount of a herbal mixture, and an anti-BPH agent to said subject where said herbal mixture comprises Astragalus membranaceus and Glycine max; and compositions thereof.
    Type: Application
    Filed: August 18, 2015
    Publication date: February 23, 2017
    Inventor: Sheng-Yung Liu
  • Publication number: 20170049835
    Abstract: A shampoo, conditioner, cream, ointment or other topical scalp or hair treatment includes a combination of Sheng Di Huang, Da Huang and Jin Yin Hua for treating psoriasis, eczema, melanoma, dandruff and hair loss.
    Type: Application
    Filed: July 26, 2016
    Publication date: February 23, 2017
    Inventors: Nadav Shraibom, Anu T. Singh, Manu Jaggi, Eran Steinberg